At Deciphera Pharmaceuticals, we are committed to advancing improved treatments for patients with cancer. Based on our technology innovation and the insights of our cancer drug developers, we see opportunities to make advancements in areas where current therapies fall short due to drug resistance and limited durability of effect.
We have designed our pipeline of advanced kinase inhibitors to address the key limitations of cancer therapies. By blocking the cancer signaling mechanisms responsible for tumor growth, proliferation and drug resistance, our small molecule drug candidates offer the potential for improved and longer lasting cancer-fighting effects – leading to greater patient benefit. Deciphera’s proprietary switch control platform has generated a broad clinical pipeline of kinase inhibitors including tumor-targeted therapies and immuno-targeted therapies.